MATTER’s Post

Sifted's April’s early-stage funding wrapup — what did we find? 👉 Deal activity for Europe’s early-stage startups was down in April; VCs invested €1.4bn spread across 312 pre-seed, seed and Series A rounds last month 👉 The UK maintained its early-stage crown for funding in Europe (€314m), followed by France (€272m), then Germany (€211m) 👉 B2B SaaS, climate tech and healthtech took the top three spots, pulling in €345m, €333m and €315m respectively. 👉 It was a big month for healthtech, as drug discovery and biotech took the first two spots, pulling €138m and €135.2m respectively Plus, we share 12 early-stage rounds that caught our eye... #funding #venturecapital #VC

What are some of the most helpful forms of support for your Biotech Startup? Tools/frameworks, materials, equipment, consumables, a shoulder to lean on when times are tough, but what about... Experience? The benefits of co-location for innovation are immense. BioQuisitive Ltd being next to Nutromics is a great example. Having two incumbents of our innovation ecosystem so close to one another, working in different sectors/tech but still "bio" allows for the exchange of almost everything, especially stories, you never know what your going to learn listening to someone else's journey. I've heard tidbits of the Nutromics journey through the grapevine, some of it sounded unreal, but never the uncut story! From the bench to the market, this is going to be incredible. 🤘 Thank you, Peter Vranes and Warwick D. (you too, Jan Bjelic), for organizing this. #medtech #Deeptech #advancedmanufacturing #wearables #biotech #brunswick #merribek #Startup #founder

this is a useful checklist

Germany's Earlybird Venture Capital has announced a close of €173m for its second healthtech fund. Among its backers are British Patient Capital and BARMER — one of the largest public health insurers in Germany. A number of family offices, an endowment fund and a bank also invested. So where's the money going? The firm will invest between €3-8m at Series A and B, for startups in the biopharma, medtech and digital health sectors. Principal Dr. Christoph Massner tells Sifted that with big pharma companies facing an upcoming “patent cliff” — when a number of drug patents expire and the market opens up for anyone to produce them — in 2030, there's "unprecedented opportunity" in the biopharma space... with “loads more opportunities for exits”. Sifted's Kai Nicol-Schwarz digs into more below 👇 https://lnkd.in/e784T8Gm

Sword Health, a Digital Therapeutics venture founded in Portugal in 2014, has raised $30 million and enabled employees to sell $100 million worth of equity to new and existing investors, including Khosla Ventures. This latest round has elevated the 10-year-old company’s valuation to $3 billion, a 50% increase from its Series D valuation of $2 billion in November 2021. 🎉 Initially, Sword Health's Series D1 round aimed at facilitating a $100 million secondary transaction to allow employees and early investors to sell shares. However, the company also raised an additional $30 million, which will be banked for future opportunities. This strategic decision highlights Sword Health's commitment to growth and stability, even amidst the challenging fundraising environment of 2024. This latest primary round brings Sword Health’s total funding to $430 million. The company has the continued support from investors, including Khosla Ventures, General Catalyst, BOND, Founders Fund, and many others. Sword Health's journey from a startup in Portugal to a thriving growth-stage venture in the US market is a testament to its innovative approach and dedicated team. 🌟 For more insights into Sword Health’s journey and impact, check out the attached venture profile, powered by HealthTech Alpha. #DigitalHealth #europe

Here's a recap of pitches, panel discussions, fast rounds, and what I learned from the Project MedTech Midwest Showcase! https://hubs.ly/Q02Dz_k60 #medtech #medicaldevice #investors #founders #pitch #startups #funding

15 Most Active HealthTech VC Players (aka the folks fueling health tech's big leaguers) Totally geeking out over #digitalhealth #unicorns, which means I'm all about the VCs backing them. So, here's the lowdown on the 15 shakers in the #VC world Let's roll. 🕵♂️ SOSV 💰 Latest funding: $400m 🦄 Portfolio unicorns: Opentrons Labworks Inc. 🕵♂️ New Enterprise Associates (NEA) 💰 Latest funding: $3b 🦄 Portfolio unicorns: Comanche Biopharma Perplexity 🕵♂️ OrbiMed 💰 Latest funding: $1.9b 🦄 Portfolio unicorns: Edgewise Therapeutics OnCusp Therapeutics 🕵♂️ Khosla Ventures 💰 Latest funding: $550m 🦄 Portfolio unicorns: Headspace Berkshire Grey 🕵♂️ Polaris Partners 💰 Latest funding: $285m 🦄 Portfolio unicorns: Iora Health Fate Therapeutics Inc 🕵♂️ ARCH Venture Partners 💰 Latest funding: $3b 🦄 Portfolio unicorns: Juno Therapeutics, Inc. Prime Medicine, Inc. Altos Labs 🕵♂️ RA Capital Management 💰 Latest funding: $880m Portfolio unicorns: Prevail Therapeutics 🕵♂️ Sequoia Capital 💰 Latest funding: $195m Portfolio unicorns: Loom 🕵♂️ Versant Ventures 💰 Latest funding: $560m 🦄 Portfolio unicorns: Ambrx 🕵♂️ Qiming Venture Partners 💰 Latest funding: CNY6.5b 🦄 Portfolio unicorns: Zhipu AI 🕵♂️ Venrock 💰 Latest funding: $450m 🦄 Portfolio unicorns: Vocera Communications, now part of Stryker 🕵♂️ Bpifrance 💰 Latest funding: $50m 🦄 Portfolio unicorns: Talend ManoMano Swile 🕵♂️ Kleiner Perkins 💰 Latest funding: $800m 🦄 Portfolio unicorns: Silicon Spice Loom 🕵♂️ Novartis Venture Fund 💰 Latest funding: $200m 🦄 Portfolio unicorns: Merus N.V. Athelas 🕵♂️ MPM Capital 💰 Latest funding: $850m 🦄 Portfolio unicorns: argenx Nevro ---- Found it helpful? Repost ♻️ PS - inspired by Dr. Derrick Khor post. 📌 PS - what's your fav healthcare unicorn?

It's #fundraising 💸 season! Read our latest blog for insights for Success 👇 #medtechstartup #meddevice #fundraising #investinyourbrand

🚀 Paperbox Health, a startup from our 2022 acceleration program, has secured €𝟐𝟑𝟎𝐊 𝐢𝐧 𝐚 𝐛𝐫𝐢𝐝𝐠𝐞 𝐫𝐨𝐮𝐧𝐝, showcasing their continued progress.   🌐 An idea born during the first edition of Vento and built upon through VITA Accelerator, Paperbox offers an accessible screening method for Learning Disorders. The recent bridge round, backed by 𝐕𝐈𝐓𝐀 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐨𝐫 and 𝐆𝐞𝐧𝐞𝐑𝐚, marks a significant milestone in their journey.   👥 Collaborating with Gemelli Digital Medicine & Health — GDMH, the startup is set to conduct pre-clinical usability tests for 𝐃𝐈𝐍𝐎 𝐛𝐲 𝐏𝐚𝐩𝐞𝐫𝐛𝐨𝐱, their solution for dyslexia. The tool's public release is anticipated in 2024, representing a major step in early identification and preventive intervention for childhood cognitive disorders.   💡 The funds raised will propel Paperbox towards clinical trials, medical certification, solution development, go-to-market validation, and expanding their user base.   👉 Curious to learn more about Paperbox Health's journey? Dive into the details: https://lnkd.in/dZKHKbYv   And if you're ready to join us for our 2024 Program, submit your application: https://lnkd.in/dwdqXhuN   #VITAAccelerator #Startup #DigitalHealth #Innovation #SLD

Swedish #heartfailure startup Acorai closes €4.1 million to change the paradigm on acute care settings. Helsingborg-based Acorai, a startup medical device manufacturer from Sweden, has announced closing an oversubscribed €4.1 million seed round led by Solardis Health Ventures, with participation from KHP Ventures, Carma Fund and other US investors. Significant follow-on investment was taken from existing investors from across Sweden and the EU. The capital will help to finance its clinical studies and move towards regulatory approval, which comes off the back of €2.3 million in non-dilutive grant and €10 million in future equity financing from the European Innovation Council (EIC). https://lnkd.in/en94zYpq #digitalhealth #heartdisease #cardiovascularhealth